

Title: Environmental exposures are important risk factors for advanced liver fibrosis in African American adults: NHANES 1999-2018

Authors: Ning Ma¹, Rowena Yip², Sara Lewis², Amreen Dinani¹, Christina Wyatt³, Michael Crane⁴, Artit Jirapatnakul², Li Li¹, Costica Aloman⁵, Meena B. Bansal¹, Douglas Dieterich¹, Brooke Wyatt¹, David Yankelevitz², Claudia Henschke², Andrea D. Branch¹

¹ Division of Liver Diseases, Icahn School of Medicine Mount Sinai, New York, NY, USA

² Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

³ Department of Medicine, Division of Nephrology, Duke University School of Medicine, Durham, NC, USA.

⁴ Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

⁵ Department of Medicine, Rush University Medical Center, Chicago, IL, USA

Corresponding author: Andrea D. Branch

Professor of Medicine

Division of Liver Diseases

Director of Basic and Translational Research Institute of Liver Medicine

Icahn School of Medicine at Mount Sinai

One Gustave L. Levy Place, Box 1123, New York, NY 10029

E-mail: andrea.branch@mssm.edu

Tel: +1-212-659-8371

Fax: 1-212-849-2574

Keywords: environmental toxins, racial disparities, etiology, non-invasive scores, screening

Electronic word count: 5,677 words

Number of figures and tables: 5 figures and 3 table

Conflict of interest statement: All authors declare no relevant or material financial interests that relate to the research described in this paper.

Financial Support: National Institute for Occupational Safety and Health (NIOSH): U01

OH01163

Author Contributions:

Formal analysis: Ning Ma, Rowena Yip.

Methodology: Ning Ma, Rowena Yip, Sara Lewis, Amreen Dinani, Christina Wyatt, Michael Crane, Artit Jirapatnakul, Li Li, Costica Aloman, Meena B. Bansal, Douglas Dieterich, Brooke Wyatt, David Yankelevitz, Claudia Henschke, Andrea D. Branch.

Manuscript Draft: Ning Ma, Andrea D. Branch.

Manuscript review and editing: All authors.

Funding acquisition: Andrea D. Branch

Abstract

Background and aims: The prevalence and etiology of liver fibrosis vary over time and impact racial/ethnic groups unevenly. This study measured time-trends and identified factors associated with advanced liver fibrosis in the U.S.

Methods: Standardized methods were used to analyze data on 47,422 participants (≥ 20 years) in the National Health and Nutrition Examination Survey (1999-2018). Advanced liver fibrosis was defined as Fibrosis-4 ≥ 2.67 and/or Forns Index ≥ 6.9 and elevated ALT.

Results: The estimated number of people with advanced liver fibrosis increased from 1.3 million (95% CI, 0.8-1.9) to 3.5 million (95% CI, 2.8-4.2), a nearly 3-fold increase. Prevalence was higher in non-Hispanic Black and Mexican American persons than in non-Hispanic White persons. In multivariable logistic regression analysis, cadmium was an independent risk factor in all racial/ethnic groups. Smoking and current excessive alcohol use were risk factors in most. Importantly, non-Hispanic Black persons had a distinctive set of risk factors compared to non-Hispanic White persons that included poverty (OR = 2.09; 95%CI, 1.44-3.03), and susceptibility to lead exposure (OR = 3.25; 95%CI, 1.95-5.43), but did not include diabetes (OR = 0.88; 95% CI, 0.61-1.27, $P = 0.52$). Non-Hispanic Black persons were more likely to have high exposure to lead, cadmium, polychlorinated biphenyls, and poverty than Non-Hispanic White persons.

Conclusions: The number of people with advanced liver fibrosis has increased, creating a need to expand the liver care workforce. The risk factors for advanced fibrosis varied by racial/ethnicity. These variations provide useful information for the design of screening programs. Poverty and toxic exposures were associated with the high prevalence of advanced liver fibrosis in non-Hispanic Black persons and need to be addressed.

Keywords: environmental toxins, racial disparities, etiology, non-invasive scores, screening

Lay summary: Because liver disease often produces few warning signs, simple and inexpensive screening tests that can be performed by non-specialists are needed to allow timely detection and linkage to care. This study shows that non-Hispanic Black persons have a distinctive set of risk factors that need to be taken into account when designing liver disease screening tests. Exposure to exogenous toxins may be especially important risk factors for advanced liver fibrosis in non-Hispanic Black persons.

Introduction

Liver disease causes an estimated two million deaths globally each year¹ but is under-diagnosed. In a recent U.S. study, nearly 50% of primary care patients who experienced a serious liver-related event did not have a prior diagnosis of liver disease.² Similarly, in the United Kingdom, “around three-quarters of patients who will die from cirrhosis are currently unaware that they have liver disease”.³ Increased diagnosis will require screening for liver fibrosis in primary care settings.

The Fibrosis-4 (FIB-4) index is a validated marker of liver fibrosis (LF).^{4,5} An American Gastroenterology Association task force reported that it provides a ‘useful, inexpensive, first-line assessment of liver fibrosis for use in primary care.’⁵ The Forns index is a second well-validated non-invasive fibrosis test.⁶ In the National Health and Nutrition Examination Survey (NHANES) population, FIB-4 ≥ 2.67 and Forns ≥ 6.9 have hazard ratios (HR)s for liver-related death of 42 and 117, respectively.⁴ When combined with alanine aminotransferase (ALT) elevation, both FIB-4 and Forns indices had areas under the receiver operating curve (AUROC) of 0.83 for predicting serious liver-related events over ten years in the community setting.⁶ Several additional screening tests have been proposed and it is likely that one or more will be broadly implemented soon.⁶⁻⁸

The American Association for the Study of Liver Diseases is currently developing guidelines for non-invasive LF screening.⁹ According to guidelines of the European Society for the Study of Liver (EASL),¹⁰ screening should be limited to individuals with known risk factors, such as type 2 diabetes. This restriction raises questions about which risk factors can be relied on to yield equitable and inclusive screening protocols.

Comprehensive information about risk factors in the multiethnic population of the United States (US) is lacking, but essential, particularly if screening is going to be limited to patients with

specific risk factors. Given the high accuracy of FIB-4 and Forns indices when combined with elevated ALT to identify individuals at high risk for liver-related events,⁶ the objectives of this study are to use the nationally-representative NHANES data: a) to determine time-trends, b) to compare risk factors among racial/ethnic groups, and c) to determine the percentage of people with advanced LF who might be missed by etiology-based screening. The results show that the prevalence of advanced fibrosis nearly doubled over the past twenty years and was higher in Non-Hispanic Black (NHB) than in Non-Hispanic White (NHW) persons. NHB persons had a distinctive set of risk factors that included lead (Pb) and poverty but did not include diabetes or hypertension, which were risk factors in NHW persons. These differences need to be considered in risk factor-based screening guidelines. High cadmium exposure was a risk factor in all racial/ethnic groups, highlighting the potential role of environmental toxins in liver fibrosis.

Materials and Methods

Study population and data sources

NHANES uses standardized procedures to collect data under a protocol approved by the National Center for Health Statistics Research Ethnic Review Board. Analysis of de-identified NHANES data is exempt from IRB review.¹¹ Ten cycles of NHANES (1999-2018) were used in the main analyses. Sub-studies used liver ultrasound data from NHANES III (1988-1994), and measurements of organic chemicals [polychlorinated biphenyls (PCB)] from NHANES 2003-2004. The public-use linked mortality file was obtained through 2019.¹²

Indicators of fibrosis

FIB-4 and Forns indices were calculated as before.⁴ Advanced LF was indicated by FIB-4 ≥ 2.67 and/or Forns ≥ 6.9 and ALT above upper limit of normal (ULN) (≥ 40 IU/L for men, ≥ 31 IU/L for women).

Demographic variables

Analysis used self-reported sex (male/female) and race/ethnicity [NHW, NHB, Mexican American (MA) and other (O) race (non-MA Hispanics and others)]. The main analysis was performed on people aged 20-85 years. Sensitivity analyses were conducted on people aged 35-64 because FIB-4 may under-estimate fibrosis in individuals younger than 35¹³ and because changes in health insurance may alter association with poverty after age 64.

Definition of risk factors

Kidney insufficiency (KI) was a urinary albumin to creatinine ratio (UACR) $\geq 30\text{mg/g}$ and/or an estimated glomerular filtration rate (eGFR) $< 60\text{ml/min/1.73m}^2$ calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 creatinine-based formula (race agnostic).¹⁴ Diabetes was self-reported, and/or hemoglobin A1c (HbA1c) $\geq 6.5\%$, and/or fasting plasma glucose (FPG) $\geq 126\text{mg/dL}$.¹⁵ Hypertension was systolic blood pressure (SBP) $\geq 130\text{mmHg}$, and/or diastolic blood pressure (DBP) $\geq 80\text{mmHg}$, and/or use of anti-hypertensive medication.¹⁶ Body mass index (BMI) was categorized as normal weight ($< 25\text{Kg/m}^2$), overweight ($25 \leq \text{BMI} < 30\text{Kg/m}^2$), and obese ($\geq 30\text{Kg/m}^2$). Waist circumference (WC) was categorized as normal ($< 94\text{cm}$ for men, $< 80\text{cm}$ for women), moderate ($94 \leq \text{WC} < 102\text{cm}$ for men, $80 \leq \text{WC} < 88\text{cm}$ for women) and high ($\geq 102\text{cm}$ for men, $\geq 88\text{cm}$ for women).¹⁷ Metabolic syndrome was defined as ≥ 3 of the following: WC $\geq 102\text{cm}$ for men and $\geq 88\text{cm}$ for women; triglyceride $\geq 150\text{mg/dL}$; HDL cholesterol $< 40\text{mg/dL}$ for men and $< 50\text{mg/dL}$ for women; SBP $\geq 130\text{mmHg}$ or DBP $\geq 85\text{mmHg}$ or taking hypertension medications; FPG $\geq 100\text{mg/dL}$.¹⁸ Past/current smokers answered “Yes” to the question “Have you smoked at least 100 cigarettes in your lifetime?”, never smokers answered “No”.¹⁹ The responses to questions about alcohol consumption were used to create four mutually exclusive groups, lifetime abstainers (< 12 drinks in lifetime), former drinkers (≥ 12 drinks in their lifetime but none in the past year), non-excessive current drinkers (on average, ≤ 14 drinks/week for men and ≤ 7 drinks/week for women, and never five or more in a single day during the past year for either), and excessive current drinkers (on average, > 14 drinks/week for

men and >7 drinks/week for women, or >5 drinks in a single day at least once during the past year for either).²⁰ Blood levels of lead and cadmium were analyzed as continuous and binary variables [quartiles (Q)1-3 versus Q4]. Lipid-adjusted plasma levels of PCBs were classified by quartiles (Q1-3 versus Q4) (see Fig. S6 for details).²¹ Poverty was defined as a family poverty-income-ratio below 1.0.²²

Definitions of disease etiologies

Disease etiology was examined in participants who had data for calculating the US Fatty Liver Index (USFLI), which was previously validated for the US population.²³ Viral hepatitis (VH) was past/current infection with hepatitis B virus (HBV), positive core antibody or surface antigen; or hepatitis C virus (HCV), RNA or antibody; Alcohol-associated liver disease (ALD) was meeting previous criteria²⁴ and/or categorized as current excessive drinker²⁰ in this study; Non-alcoholic fatty liver disease (NAFLD) was USFLI ≥ 30 ,²³ and No Exposure Identified (NEI) was not meeting criteria for VH, ALD or NAFLD. In sensitivity analyses, NAFLD was defined by abdominal ultrasound (mild/moderate/severe fatty liver) from NHANES III.

Statistical Analysis

All analysis were conducted according to NHANES guideline,¹¹ using established methods to combine cycles. Data were adjusted for the complex NHANES design with strata, primary sampling units, and probability weights incorporated into statistical models using the survey estimation commands in SAS OnDemand for Academics (SAS Institute Inc., Cary, NC, USA). These procedures generate estimates for the housed, civilian, non-institutionalized population in the US. Age standardization estimates were calculated using the direct method, standardized to the 2000 US census population with four age categories for the 20-85 year age group and three age categories for the 35-64 year age group. Differences between groups were tested by univariate t statistics.²⁵ To estimate the number of adults with advanced LF, prevalence was

calculated and then multiplied by the estimated adult US population obtained from the Current Population Surveys or American Community Survey of each survey cycle.²⁶ Annual percent changes (APC) were calculated using the Joinpoint Regression Program (Version 4.9.0.0, National Cancer Institute).²⁷ Univariable and multivariable survey logistic regression with appropriate sample weights were used to examine the association between advanced LF and the independent variables. Survey-weighted adjusted multivariable cox proportional models were used to investigate the association between advanced-LF and all-cause mortality. Missing values that ranged from 0.1% to 9.0% and were addressed using multivariable imputation by chained equations.²⁸ Combined estimates using ten imputed datasets were calculated. Statistical significance was a two-sided P value <0.05.

Results

Three-fold increase in cases of advanced LF over 20 years

The selection of the study group is presented in Fig. 1 and the dynamic time-trends of advanced LF are presented in Fig. 2. The estimated number of people with advanced LF increased from 1.3 million (95% CI, 0.8-1.9) to 3.5 million (95% CI, 2.8-4.2), a nearly 3-fold increase over 20 years (Fig. 2A). The age-standardized weighted prevalence approximately doubled (Fig. 2B). The annual percent change (APC) was 8.7% (95% CI, 6.7-10.9) (Table S1). The prevalence of advanced LF was about 1.6-fold higher in NHB than in NHW in the total group and in men and women when analyzed separately (Fig. 2C, D). The HR for all-cause mortality among people with advanced LF was 2.42 (95% CI, 1.96-2.97) in the 20-85 age group and 3.86 (95% CI, 2.78-5.37) in the 35-64 age group (Fig. 1B, C).

Associated conditions

The age-standardized weighted prevalence of advanced LF was compared between people with and without health conditions that might be considered as eligibility criteria in risk factor-based

screening. Several conditions differed by race/ethnicity. The prevalence of advanced LF was about 2-fold higher in those with diabetes in the total population and in NHW, MA and O, but not in NHB (total, males, and females) (Fig. 3A and Fig. S1,2); similar results were obtained when alternative definitions of diabetes were used, underscoring the robustness of the finding (Fig. S3). Only 35% (95% CI, 29.9-40.1) of participants with advanced LF had diabetes and thus 65% of cases would be missed if screening were limited to people with diabetes. Associations between obesity and advanced LF also differed by race/ethnicity. The prevalence of fibrosis was significantly higher in MA and O with obesity than in those with normal BMI (Fig. 3C). Strikingly, however, among NHB, the prevalence was about 2-fold higher in those with *normal* BMI than in those with obesity, with similar results were obtained for waist circumference (Fig. S4). Poverty was associated with advanced LF in NHB, but not in any other racial/ethnic group. Of the six conditions that reflect exposure to exogenous toxins, four (smoking, current excessive drinking, cadmium exposure, and lead exposure) were associated with advanced LF in the total population, in NHW, and in NHB (Fig. 3F, I, K, L). Former drinkers had a higher prevalence of advanced LF in NHB (Fig. 3G). In sensitivity analyses, similar results were obtained when a less restrictive definition of LF (without the requirement for ALT elevation) was used (Fig. S5).

Prevalence of risk factors

Compared to NHW, NHB had a lower prevalence of smoking and excessive drinking; however, they had a higher prevalence of many other conditions, including diabetes. Thus, the disconnection between diabetes and advanced LF in NHB does not result from a low prevalence of diabetes. NHB also had a higher prevalence of KI, hypertension, obesity, poverty, and exposure to environmental pollutants, as indicated by higher blood levels of lead, cadmium, and PCBs (Fig. 4). Both heavy metals and organic chemicals are associated with liver disease.^{21, 29, 30}

Conditions independently associated with advanced LF

Multivariable logistic regression was used to identify factors independently associated with advanced LF. Variables included age, sex, KI, diabetes, hypertension, BMI, alcohol use, smoking, and poverty. Two age groups were analyzed (20-85 and 36-64 years). In the 20-85 age group, smoking and current excessive drinking were risk factors in both NHW and NHB (Table 1). Diabetes and hypertension were independently associated with advanced LF in NHW, but not in NHB. Conversely, poverty was a risk factor in NHB, but not in NHW. In a sensitivity analysis that excluded participants with viral hepatitis, generally similar odds ratios (OR)s obtained; among NHB, the OR for diabetes was 0.76 (95% CI, 0.39-1.48) and the OR for smoking 3.00 (95% CI, 1.56-5.78) (Table S2). When metabolic syndrome was included (rather than diabetes, hypertension, and obesity), it was associated with advanced LF in the total group (Table S3). Results for the 20-85 and the 35-64 age groups were generally similar; however, in the 35-64 age group, KI was a risk factor for advanced LF in NHW; and poverty was a risk factor in NHW, as well as in NHB (Table S4). KI was an independent risk factor in all racial/ethnic groups in a sensitivity analysis that used the less restrictive definition of LF (Table S5).

Environmental exposures and advanced LF

High blood levels of cadmium, as indicated by measurements in the 4th quartile (Q4), were associated with advanced LF in the total population and in NHW, NHB, and MA in multivariable logistic regression analysis (Table 2). Blood levels of lead were strongly associated with advanced LF in NHB, but not in NHW: OR = 3.25 (95% CI, 1.95-5.43) vs. 1.24 (95% CI, 0.79-1.94, P=0.34) (Table 3). Associations between advanced LF and heavy metal exposures were dose-dependent for both cadmium and lead (Table S6,7).

NHANES 2003-2004 measured lipid-adjusted plasma levels of PCBs in 1,242 adults (Fig. S6). Over 95% of the participants with advanced LF had high PCB exposure (Fig. 5). The small sample size precluded an analysis by race/ethnicity.

Time-trends of health conditions from 1999-2000 to 2017-2018

To identify factors that might underlie the increase in advanced LF and to determine whether the 8.7% APC was typical of other diseases, we examined time-trends for 13 other conditions (Table S1). The age-standardized-weighted prevalence of high lead and cadmium exposure decreased, as did the percentage of former drinkers in the total population, in NHW, and in NHB. Smoking decreased in the total population, but the decrease was not significant among NHB. KI, hypertension, and current non-excessive drinking did not change significantly. Diabetes increased 1.6-fold in the total population (APC=4.9%) and in all groups except NHB. Obesity, as defined by either BMI or WC, increased; however, obesity was not associated with advanced LF in multivariable logistic regression analyses. LF without the requirement for ALT elevation increased 2.0-fold in the total population (APC=10.7%), suggesting that advanced LF may continue to rise in the future (Table S1). Current excessive drinking increased significantly in the total population (APC=2.3%) and increased 1.8-fold in NHB (APC=5.8%), underscoring the importance of alcohol in liver fibrosis.

Fibrosis in adults with no exposure identified (NEI)

Screening is often used to detect patients with *specific* liver diseases. We investigated the percentage of people with advanced LF who might be missed if the population were screened for the three major liver diseases, VH, ALD, and NAFLD, rather than for fibrosis. One analysis used the USFLI to define NAFLD (n=20,388). Among the 285 with advanced LF, 36 (12.8%, 95% CI, 7.5-18.0) did not meet criteria for VH, ALD, or NAFLD. A second analysis used ultrasound to define NAFLD (n=12,811 NHANES III participants). Among the 84 with advanced LF, 10 (13.9%, 95% CI, 3.6-24.2) did not meet criteria for VH, ALD, or NAFLD (Fig. S7,8). In sensitivity analyses that used LF without the requirement for ALT elevation, almost 40% of the cases were in the no exposure identified (NEI) category (Fig. S9,10). This corresponds to 3.24 million U.S. adults averaged over the time-period analyzed. Multivariable logistic regression

identified KI as a risk factor for LF in the NEI category (Table S8). These findings suggest that a significant percentage of advanced LF occurs in individuals who could be missed in etiology-based screening programs.

Discussion

This study used nationally representative data to evaluate dynamic changes in the prevalence of advanced LF and to identify risk factors in the multi-ethnic U.S. population. The results provide valuable information for the design of liver disease screening tests. The study had three major findings.

First, during the past 20 years, the prevalence of advanced LF approximately doubled and increased more rapidly than 13 other conditions. The number of people with advanced LF increased nearly 3-fold, reaching about 3.5 million in the 2017-2018 NHANES cycle. Liver services will need to expand to care for these patients. Only diabetes increased more than 1.5-fold in the total population (APC, 4.9%), which makes the increase in advanced LF (APC, 8.7%) especially noteworthy. While diabetes rose among NHW, it did not increase significantly in NHB. Conversely, current excessive drinking increased 1.8-fold (APC, 5.8%) among NHB and may be an important driver. Excessive current drinking increased about 1.2-fold in the total population (APC, 2.3%), underscoring the need to reduce harmful drinking.

Second, advanced LF was strongly associated with heavy metal (lead and cadmium) exposure and over 95% of participants with advanced LF had high lipid-adjusted levels of PCBs. These findings add to published data^{21, 29-33} and should prompt a more extensive examination of toxic exposures in liver disease. Importantly, the World Health Organization classifies cadmium as a known human carcinogen.³⁴ Additional factors independently associated with advanced LF were older age, male sex, diabetes, hypertension, excessive current drinking, past/current smoking, and poverty. Kidney insufficiency was independently associated with advanced LF in the 35-64

year age group, consistent with previous reports.^{35, 36} The association between LF and KI may reflect the shared roles of the liver and kidney in metabolism, detoxification, and excretion.

Third, NHB (both men and women) had a higher prevalence of advanced LF than their NHW counterparts and different risk factors. These results add to past evidence that NHB have a distinctive pattern of liver disease presentation and genomic factors.^{32, 37-40} A previous analysis of NHANES data also showed that NHB have a higher prevalence of cirrhosis,⁴¹ while, other studies reported a lower prevalence of biopsy-defined advanced LF among NHB.⁴² Because NHB are often under-represented in clinical trials,⁴³ and may have incomplete medical records and less access to healthcare,⁴⁴ nationally representative samples, as provided by NHANES, are especially important. Diabetes was independently associated with advanced LF in NHW⁴⁵ and O, but not in NHB, as shown before,⁴⁵ or in MA, which is consistent with published data, as past studies did not adjust for hypertension and kidney insufficiency.⁴⁶ Among NHB, high blood levels of lead were strongly associated with advanced liver fibrosis (OR=3.25) and poverty was also a risk factor. Poverty is associated with workplace and environmental toxic exposures.⁴⁷ High blood levels of PCBs were strongly associated with advanced LF and NHB had higher blood levels than NHW. Compared to NHW, NHB have a higher prevalence of a polymorphism in the gene encoding arylsulfatase A, a metabolic regulator³² associated with neurotoxicity,³³ and they develop lung cancer at younger ages and with fewer pack-years of smoking,³¹ suggesting they may be especially vulnerable to toxic injury. In this study, NHB had a higher prevalence of KI, hypertension, obesity, poverty, and exposure to environmental pollutants (lead, cadmium, and PCB). These disparities could be associated with their reduced longevity.⁴⁸

The study provided intriguing evidence that even if everyone in the U.S. were fully screened for VH, ALD, and NAFLD (don't hold your breath), 12-40% of significant LF might be missed. These findings are consistent with data showing that about 20% of cirrhosis-related deaths occur in people without any of the major liver diseases,⁴⁹ and with results showing that liver disease

etiology was unspecified in 48% of cirrhosis- or hepatocellular carcinoma-related deaths in the U.S.⁵⁰ These findings highlight the advantage of universal screening for advanced liver fibrosis. At a negligible cost, electronic health records could flag patients with FIB-4 ≥ 2.67 and/or Forns ≥ 6.9 and ALT \geq ULN, providing a realistic backstop to risk factor-based and etiology-based screening and offering a safety net for the high percentage of non-diabetics whose liver disease has not been diagnosed.

Limitations

The main limitations are: a) the use of NHANES data, which are collected cross-sectionally at a single time point and are restricted to the housed non-institutionalized population; b) the use of the FIB-4/Forns scores and USFLI to define LF and NAFLD, rather than histopathology; c) the use of self-reported data to define race/ethnicity, alcohol use, and smoking habits. The study could not assess causality. To mitigate these limitations, we a) acknowledge them here, b) performed weighted and age-standardized analyses, which adjust for changes in the age and demographic structure of the population, and c) used ultrasound to define NAFLD in confirmatory studies.

Conclusions:

In the U.S., the prevalence of advanced LF doubled over the past 20 years and was higher in NHB (total group and men and women) than in NHW (total group and men and women). Liver care services will need to expand to meet the increased liver disease burden. Toxic exposures had especially strong associations with LF in NHB, suggesting that NHB may be particularly vulnerable. Poverty, smoking, excessive drinking, and exposure to environmental toxins are potentially modifiable LF risk factors. Universal screening with FIB-4 ≥ 2.67 and/or Forns ≥ 6.9 and ALT \geq ULN would be a realistic backstop to risk factor-based screening.

Abbreviations :

Alcohol-associated liver disease (ALD); Alanine aminotransferase (ALT); Area under the receiver operating curve (AUROC); Body mass index (BMI); Confidence interval (CI); Fibrosis-4 (FIB-4) score; Kidney insufficiency (KI); Hazard ratio (HR); Liver fibrosis (LF); Mexican American (MA); Non-Hispanic White (NHW); Non-Hispanic Black (NHB); Non-alcoholic fatty liver disease (NAFLD); National Health and Nutrition Evaluation Survey (NHANES); No exposure identified (NEI); Polychlorinated biphenyls (PCB); Quartile (Q); Viral hepatitis (VH)

Acknowledgements: The authors thank Dr. Kerry Willis (National Kidney Foundation) for highlighting the likely importance of kidney insufficiency. This work was supported by National Institute for Occupational Safety and Health (NIOSH): U01 OH01163.

Supplementary material is available on the preprint site.

Reference

1. **Asrani SK, Devarbhavi H**, Eaton J, et al. Burden of liver diseases in the world. *J Hepatol* 2019;70:151-171.
2. Schreiner AD, Zhang J, Moran WP, et al. FIB-4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: A Fine-Gray competing risk analysis. *Liver Int* 2022.
3. OHID. Guidance of Liver disease: applying All Our Health. Office for Health Improvement and Disparities (OHID) in England, <https://www.gov.uk/government/publications/liver-disease-applying-all-our-health/liver-disease-applying-all-our-health>.
4. Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. *Hepatology* 2017;66:84-95.
5. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2021;161:1657-1669.
6. Hagström H, Talbäck M, Andreasson A, et al. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. *Gastroenterology* 2020;158:200-214.
7. Sripongpun P, Kim WR, Mannalithara A, et al. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. *Hepatology* 2022.
8. **Eskridge W, Vierling JM**, Gosbee W, et al. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). *PLoS One* 2021;16:e0260320.
9. AASLD. Practice Guidelines are in development. <https://www.aasld.org/practice-guidelines>
10. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatol* 2021;75:659-689.
11. Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. *Vital Health Stat 2* 2013;1-24.
12. NCHS Data Linkage. <https://www.cdc.gov/nchs/data-linkage/mortality-public.htm>.
13. McPherson S, Hardy T, Dufour J-F, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Hepatology* 2017;112:740.
14. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *N Engl J Med* 2021;385:1737-1749.
15. Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of diabetes by race and ethnicity in the United States, 2011-2016. *Diabetes Care* 2019;322:2389-2398.
16. Lamprea-Montealegre JA, Zelnick LR, Hall YN, et al. Prevalence of Hypertension and Cardiovascular Risk According to Blood Pressure Thresholds Used for Diagnosis. *Hypertension* 2018;72:602-609.
17. Welborn TA, Dhaliwal SS. Preferred clinical measures of central obesity for predicting mortality. *Eur J Clin Nutr* 2007;61:1373-9.
18. Hirode G, Wong RJ. Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. *Jama* 2020;323:2526-2528.
19. **Jaber RM, Mirbolouk M**, DeFilippis AP, et al. Electronic Cigarette Use Prevalence, Associated Factors, and Pattern by Cigarette Smoking Status in the United States From NHANES (National Health and Nutrition Examination Survey) 2013-2014. *J Am Heart Assoc* 2018;7.
20. Taylor AL, Denniston MM, Klevens RM, et al. Association of hepatitis C virus with alcohol use among US adults: NHANES 2003–2010. *Alcohol Clin Exp Res* 2016;51:206-215.

21. Cave M, Appana S, Patel M, et al. Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003–2004. *2010*;118:1735-1742.
22. Freedman DS, Ogden CL, Flegal KM, et al. Childhood overweight and family income. *MedGenMed* 2007;9:26.
23. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. *Aliment Pharmacol Ther* 2015;41:65-76.
24. Dang K, Hirode G, Singal AK, et al. Alcoholic Liver Disease Epidemiology in the United States: A Retrospective Analysis of 3 US Databases. *Am J Gastroenterol* 2020;115:96-104.
25. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. *NCHS Data Brief* 2020:1-8.
26. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. *Hepatology* 2019;69:1020-1031.
27. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. *2000*;19:335-351.
28. Yuan YCJSII, Rockville, MD. Multiple imputation for missing data: Concepts and new development (Version 9.0). *2010*;49:12.
29. Reja D, Makar M, Visaria A, et al. Blood lead level is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease: A nationwide survey (NHANES 2011–2016). *2020*;19:404-410.
30. Hyder O, Chung M, Cosgrove D, et al. Cadmium exposure and liver disease among US adults. *J Gastrointest Surg* 2013;17:1265-73.
31. Prosper A, Brown K, Schussel B, et al. Lung cancer screening in African Americans: the time to act is now. *2020*;2.
32. Montgomery MK, Bayliss J, Nie S, et al. Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemc control. *2022*;13:1-18.
33. Taylor JY, Wright ML, Housman DJNgm. Lead toxicity and genetics in Flint, MI. *2016*;1:1-2.
34. Organization WH. Preventing disease through healthy environments: exposure to cadmium: a major public health concern: World Health Organization, 2019.
35. Ciardullo S, Ballabeni C, Trevisan R, et al. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. *Dig Liver Dis* 2021;53:866-872.
36. Wijarnpreecha K, Thongprayoon C, Scribani M, et al. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. *Eur J Gastroenterol Hepatol* 2018;30:404-410.
37. Wang L, Sinnott-Armstrong N, Wagschal A, et al. A MicroRNA Linking Human Positive Selection and Metabolic Disorders. *Cell* 2020;183:684-701.e14.
38. Rich NE, Oji S, Mufti AR, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2018;16:198-210.e2.
39. Winters AC, Shaltiel T, Sarpel U, et al. Liver Cancer Has a Distinctive Profile in Black Patients: Current Screening Guidelines May Be Inadequate. *Hepatol Commun* 2022;6:8-11.
40. Shaltiel T, Zheng S, Siderides C, et al. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. *Cancer* 2021;127:1395-1406.
41. Scaglione S, Kliethermes S, Cao G, et al. The Epidemiology of Cirrhosis in the United States: A Population-based Study. *J Clin Gastroenterol* 2015;49:690-6.

42. Satapathy SK, Marella HK, Heda RP, et al. African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians. *Eur J Gastroenterol Hepatol* 2021;33:388-398.
43. Camidge DR, Park H, Smoyer KE, et al. Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. *Future Oncol* 2021;17:3271-3280.
44. Cuevas AG, O'Brien K, Saha S. African American experiences in healthcare: "I always feel like I'm getting skipped over". *Health Psychol* 2016;35:987-95.
45. Browning MG, Khoraki J, DeAntonio JH, et al. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes. *Int J Obes (Lond)* 2018;42:926-929.
46. Jiao J, Watt GP, Lee M, et al. Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. *PLoS One* 2016;11:e0150978.
47. Rauh VA, Landrigan PJ, Claudio L. Housing and health: intersection of poverty and environmental exposures. *Ann N Y Acad Sci* 2008;1136:276-88.
48. Andrasfay T, Goldman N. Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations. *Proc Natl Acad Sci U S A* 2021;118.
49. Paik JM, Golabi P, Younossi Y, et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. *Hepatology* 2020;72:1605-1616.
50. Kim D, Li AA, Perumpail BJ, et al. Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. *Hepatology* 2019;69:1064-1074.

Author names in bold designate shared co-first authorship

Table 1. Odds ratios from multivariable logistic regression models with the outcome of advanced liver fibrosis

Cohorts	Cohort aged 20-85, OR (95% CI)				
	Total (47,442)	NHW (21,167)	NHB (9,634)	MA (8,334)	O (8,307)
Sample size (N)	642	259	149	127	107
Advanced fibrosis cases (N)	642	259	149	127	107
Age (unit 10 years)	1.58 (1.47, 1.67) ‡	1.54 (1.40, 1.69) ‡	1.55 (1.36, 1.75) ‡	1.78 (1.49, 2.13) ‡	1.98 (1.70, 2.31) ‡
Gender	Reference				
Female	Reference				
Male	1.44 (1.15, 1.87) ‡	1.47 (1.01, 2.13) *	1.43 (0.99, 2.06)	1.19 (0.69, 2.05)	1.34 (0.81, 2.22)
Kidney insufficiency	Reference				
No	Reference				
Yes	1.30 (0.99, 1.71)	1.39 (0.94, 2.06)	1.00 (0.65, 1.54)	1.04 (0.57, 1.89)	1.47 (0.86, 2.54)
Diabetes	Reference				
No	Reference				
Yes	2.23 (1.75, 2.84) ‡	2.58 (1.89, 3.52) ‡	0.88 (0.61, 1.27)	1.65 (0.93, 2.91)	2.43 (1.33, 4.44) *
Hypertension	Reference				
No	Reference				
Yes	1.63 (1.21, 2.19) *	1.70 (1.11, 2.59) *	1.25 (0.80, 1.94)	2.03 (1.14, 3.61) *	1.21 (0.65, 2.23)
BMI	Reference				
Normal	Reference				
Overweight	0.88 (0.63, 1.23)	0.81 (0.50, 1.32)	1.01 (0.61, 1.67)	1.33 (0.67, 2.68)	0.98 (0.57, 1.68)
Obese	0.93 (0.69, 1.27)	0.86 (0.56, 1.30)	0.68 (0.40, 1.14)	1.39 (0.67, 2.89)	1.74 (0.91, 3.32)
Alcohol use	Reference				
Lifetime abstainers	Reference				
Former drinkers	0.86 (0.60, 1.24)	0.84 (0.48, 1.46)	1.60 (0.87, 2.93)	0.96 (0.57, 1.63)	0.67 (0.31, 1.45)
Non-excessive current drinkers	0.93 (0.65, 1.33)	1.02 (0.59, 1.74)	1.38 (0.74, 2.58)	0.89 (0.58, 1.36)	0.57 (0.28, 1.16)
Excessive current drinkers	2.04 (1.38, 3.02) †	2.17 (1.19, 3.95) *	2.65 (1.48, 4.73) †	2.36 (1.24, 4.49) *	1.47 (0.70, 3.09)
Smoking status	Reference				
Never	Reference				
Past/current	1.68 (1.30, 2.16) †	1.67 (1.17, 2.36) *	1.79 (1.21, 2.64) *	1.41 (0.80, 2.47)	2.03 (1.09, 3.80) *
Poverty	Reference				
No	Reference				
Yes	1.49 (1.19, 1.87) †	1.25 (0.84, 1.87)	2.09 (1.44, 3.03) †	1.16 (0.69, 1.96)	1.13 (0.75, 1.71)

Multiple imputation was performed in univariate and multivariate logistic regression models. Variables with P value < 0.1 in the univariate in total cohort were included into multivariate analysis. *P < .05, †P < .001, ‡P < .0001. Abbreviations: odds ratio, OR; confidence interval, CI; body mass index, BMI; Non-Hispanic White, NHW; Non-Hispanic Black, NHB; Mexican American, MA; other race, O.

Table 2. Odds ratios from multivariable logistic regression models with the outcome of advanced liver fibrosis and added blood cadmium level into models

Cohorts	In aged 20-85 years with cadmium into models, OR (95% CI)				
	Total (42,255)	NHW (19,176)	NHB (8,585)	MA (7,508)	O (6,986)
Sample size (N)					
Advanced fibrosis cases (N)	542	226	128	102	86
Survey year	1.07 (1.03, 1.11) ‡	1.08 (1.03, 1.13) †	1.01 (0.95, 1.08)	1.10 (0.99, 1.20)	1.03 (0.94, 1.13)
Age (unit 10 years)	1.56 (1.44, 1.68) ‡	1.51 (1.36, 1.69) ‡	1.52 (1.31, 1.76) ‡	1.79 (1.46, 2.21) ‡	2.09 (1.75, 2.50) ‡
Gender					
Female	Reference				
Male	1.61 (1.24, 2.08) †	1.67 (1.16, 2.41) *	1.61 (1.08, 2.40) *	1.30 (0.71, 2.36)	1.25 (0.65, 2.40)
Kidney insufficiency					
No	Reference				
Yes	1.15 (0.85, 1.55)	1.16 (0.75, 1.79)	1.17 (0.74, 1.84)	0.58 (0.36, 0.94) *	1.54 (0.83, 2.87)
Diabetes					
No	Reference				
Yes	2.38 (1.83, 3.11) ‡	2.85 (2.05, 3.96) ‡	0.78 (0.50, 1.19)	1.97 (1.04, 3.73) *	2.60 (1.26, 5.35) *
Hypertension					
No	Reference				
Yes	1.86 (1.33, 2.58) †	2.04 (1.27, 3.27) *	1.32 (0.77, 2.24)	2.37 (1.15, 4.86) *	1.13 (0.54, 2.35)
BMI					
Normal	Reference				
Overweight	0.89 (0.60, 1.33)	0.85 (0.48, 1.49)	0.91 (0.52, 1.57)	1.15 (0.56, 2.34)	0.94 (0.43, 2.08)
Obese	0.92 (0.64, 1.32)	0.81 (0.49, 1.33)	0.80 (0.47, 1.39)	1.02 (0.46, 2.30)	2.00 (0.83, 4.85)
Alcohol use					
Lifetime abstainers	Reference				
Former drinkers	0.92 (0.61, 1.38)	0.85 (0.49, 1.47)	1.91 (0.86, 4.25)	0.84 (0.30, 2.35)	0.87 (0.33, 2.29)
Non-excessive current drinkers	1.00 (0.66, 1.52)	1.06 (0.61, 1.85)	1.41 (0.59, 3.34)	0.81 (0.26, 2.50)	0.74 (0.30, 1.82)
Excessive current drinkers	2.02 (1.30, 3.13) *	2.08 (1.12, 3.85) *	2.65 (1.19, 5.90) *	2.03 (0.63, 6.46)	1.70 (0.64, 4.57)
Smoking status					
Never	Reference				
Past/current	1.40 (1.03, 1.91) *	1.42 (0.94, 2.14)	1.23 (0.76, 2.00)	1.37 (0.67, 2.80)	1.71 (0.72, 4.06)
Poverty					
No	Reference				
Yes	1.36 (1.02, 1.80) *	1.00 (0.62, 1.62)	1.95 (1.26, 3.02) *	1.11 (0.57, 2.19)	1.06 (0.56, 2.01)
Blood cadmium level					
Q1-3	Reference				
Q4	1.81 (1.30, 2.53) †	1.75 (1.08, 2.85) *	2.01 (1.23, 3.30) *	2.24 (1.21, 4.16) *	1.75 (0.83, 3.65)

Cadmium analysis based on complete dataset with information of blood lead and cadmium measurements with N=42,255. Multiple imputation was performed in univariate and multivariate logistic regression models. Variables with P value < 0.1 in the univariate in total cohort were included into multivariate analysis. *P < 0.05, †P < 0.001, ‡P < 0.0001. Abbreviations: odds ratio, OR; confidence interval, CI; body mass index, BMI; Non-Hispanic White, NHW; Non-Hispanic Black, NHB; Mexican American, MA; other race, O.

Table 3. Odds ratios from multivariable logistic regression models with the outcome of advanced liver fibrosis and added blood lead level into models

Cohorts	In aged 20-85 years with blood lead (Pb) level into models, OR (95% CI)				
	Total (42,255)	NHW (19,176)	NHB (8,585)	MA (7,508)	O (6,986)
Sample size (N)	542	226	128	102	86
Advanced fibrosis cases (N)					
Survey year	1.08 (1.04, 1.12) ‡	1.09 (1.04, 1.14) ‡	1.07 (1.01, 1.14) *	1.06 (0.97, 1.17)	1.02 (0.92, 1.12)
Age (unit 10 years)	1.52 (1.40, 1.65) ‡	1.47 (1.31, 1.66) ‡	1.35 (1.16, 1.59) ‡	1.83 (1.49, 2.26) ‡	2.12 (1.78, 2.53) ‡
Gender					
Female	Reference				
Male	1.46 (1.11, 1.92) *	1.54 (1.04, 2.28) *	1.12 (0.72, 1.74)	1.24 (0.69, 2.22)	1.19 (0.67, 2.14)
Kidney insufficiency					
No	Reference				
Yes	1.19 (0.88, 1.59)	1.20 (0.79, 1.84)	1.01 (0.46, 2.24)	0.63 (0.38, 1.05)	1.58 (0.85, 2.93)
Diabetes					
No	Reference				
Yes	2.37 (1.82, 3.10) ‡	2.84 (2.04, 3.95) ‡	0.82 (0.53, 1.26)	1.85 (0.99, 3.44)	2.56 (1.27, 5.14) †
Hypertension					
No	Reference				
Yes	1.87 (1.34, 2.60) †	2.04 (1.27, 3.29) *	1.29 (0.76, 2.20)	2.38 (1.16, 4.89) *	1.12 (0.53, 2.35)
BMI					
Normal	Reference				
Overweight	0.85 (0.58, 1.25)	0.81 (0.47, 1.42)	0.89 (0.51, 1.56)	1.08 (0.51, 2.28)	0.87 (0.41, 1.87)
Obese	0.86 (0.61, 1.21)	0.76 (0.47, 1.22)	0.83 (0.48, 1.44)	0.93 (0.42, 2.09)	1.73 (0.70, 4.27)
Alcohol use					
Lifetime abstainers	Reference				
Former drinkers	0.91 (0.61, 1.37)	0.87 (0.50, 1.50)	1.72 (0.77, 3.87)	0.84 (0.30, 2.30)	0.86 (0.34, 2.14)
Non-excessive current drinkers	0.97 (0.64, 1.46)	1.05 (0.61, 1.81)	1.33 (0.56, 3.14)	0.78 (0.25, 2.41)	0.75 (0.31, 1.77)
Excessive current drinkers	1.96 (1.26, 3.05) *	2.05 (1.10, 3.81) *	2.38 (1.08, 5.25) *	2.07 (0.65, 6.55)	1.71 (0.66, 4.43)
Smoking status					
Never	Reference				
Past/current	1.68 (1.27, 2.22) †	1.68 (1.15, 2.45) *	1.44 (0.92, 2.25)	1.75 (0.92, 3.33)	1.96 (0.90, 4.24)
Poverty					
No	Reference				
Yes	1.36 (1.02, 1.80) *	1.07 (0.66, 1.73)	1.86 (1.19, 2.90) *	1.21 (0.64, 2.31)	1.10 (0.59, 2.06)
Blood lead level					
Q1-3	Reference				
Q4	1.32 (0.96, 1.80)	1.24 (0.79, 1.94)	3.25 (1.95, 5.43) ‡	0.72 (0.40, 1.28)	0.84 (0.39, 1.83)

Lead analysis based on complete dataset with information of blood lead and cadmium measurements with N=42,255. Multiple imputation was performed in univariate and multivariate logistic regression models. Variables with P value < 0.1 in the univariate in total cohort were included into multivariate analysis. *P < 0.05, †P < 0.001, ‡P < 0.0001. Abbreviations: odds ratio, OR; confidence interval, CI; body mass index, BMI; Non-Hispanic White, NHW; Non-Hispanic Black, NHB; Mexican American, MA; other race, O.

Fig. legends:

Fig. 1. Flowchart of participant selection and association between advanced fibrosis and all-cause mortality. (A) Flowchart of participant selection; all-cause mortality (B) in the 20-85 age group and (C) in the 35-64 age group. Association between advanced fibrosis and all-cause mortality was analyzed using survey-weighted multivariable cox proportional models (adjusted for age, sex, race/ethnicity, body mass index, alcohol and smoking status, and poverty). ALT, alanine aminotransferase; FIB-4, fibrosis-4; NHANES, National Health and Nutrition Examination Survey; ULN, upper limit of normal.

Fig. 2. Time-trends and prevalence of advanced liver fibrosis. (A) The change in the number (millions) of U.S. adults with advanced liver fibrosis (black) and fibrosis defined by FIB-4 ≥ 2.67 and/or Forns ≥ 6.9 (grey) overtime with 95% confidence intervals (CI) (dashed); (B) age-standardized weighted prevalence of advanced fibrosis (black) and fibrosis (grey) over time. Age-standardized weighted prevalence of advanced fibrosis (C) in people 20-85 years old and (D) in people 35-64 years old (total, males, and females), stratified by race/ethnicity. Differences between groups were tested by univariate t statistic, * $P < 0.05$. Abbreviations: Non-Hispanic White, NHW (blue); non-Hispanic Black, NHB (red); Mexican American, MA; other race, O; standard error, SE.

Fig. 3. Advanced fibrosis in participants aged 20-85 years, stratified by health conditions and race/ethnicity. The age-standardized weighted prevalence of advanced fibrosis among participants with and without various health conditions were determined for the total cohort (black), non-Hispanic White (NHW, blue), non-Hispanic Black (NHB, red), Mexican American (MA, grey) and other (light grey) racial/ethnic groups. (A) Diabetes, (B) hypertension, (C) body mass index (BMI) categories, normal (N), overweight (OW) and obese (OB), (D) metabolic syndrome, (E) kidney insufficiency, (F) current/past smokers, (G) former drinkers vs. lifetime abstainers, (H) current non-excessive drinkers vs. lifetime abstainers, (I) current excessive


drinkers vs. lifetime abstainers, (J) poverty, (K) blood levels of lead and (L) cadmium (Q1-3 vs. Q4). Differences between groups were tested by univariate t statistic. *P < 0.05, **P < 0.001, ***P < 0.0001. ^a Components of metabolic syndrome were only available for participants with fasting blood tests in NHANES 2007-2018, N=13,886. ^b Cadmium and lead analysis were based on complete datasets without imputation, N=42,255. Abbreviation: quartile, Q; standard error = SE.

Fig. 4. Prevalence of health conditions in participants aged 20-85 years, stratified by race/ethnicity. Shown are the age-standardized weighted prevalence of (A) diabetes, (B) hypertension, (C) obesity (BMI \geq 30 Kg/m²), (D) metabolic syndrome, (E) kidney insufficiency, (F) past/current smokers, (G) former drinker, (H) current non-excessive drinker, (I) current excessive drinker, (J) poverty, quartile 4 (Q4) blood level of (K) lead, (L) cadmium, and (M) total polychlorinated bi-phenyls (PCB) among non-Hispanic White (NHW, blue), non-Hispanic Black (NHB, red), Mexican American (MA), and Other race groups. ^a Components of metabolic syndrome were only available for participants with fasting blood test in NHANES 2007-2018, N=13,886. ^b Cadmium and lead analysis were based on complete datasets without imputation, N=42,255. ^c PCB data from NHANES 2003-2004 survey cycles included 1,242 participants. Differences between groups were tested by univariate t statistic, *P < 0.05, **P < 0.001, ***P < 0.0001. Abbreviation: body mass index, BMI; standard error, SE.


Fig.5. Association between advanced fibrosis and polychlorinated biphenyls (NHANES 2003-2004). (A) the age-standardized weighted prevalence of advanced liver fibrosis in people with low [quartile (Q)1-3] and high (Q4) lipid-adjusted plasma measurements of total PCBs in participants in NHANES 2003-2004. (B) distribution of advanced fibrosis cases in participants with Q1-3 (white) versus Q4 (dotted) levels of total PCBs. Differences between groups were tested by univariate t statistic, *P<0.05.

A. Flowchart of participant selection


medRxiv preprint doi: <https://doi.org/10.1101/2022.11.29.22282889>; this version posted November 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).







B. All-cause mortality in 20-85 age group




C. All-cause mortality in 35-64 age group







■ All ■ NHW ■ NHB ■ MA ■ Other




A. Diabetes




B. Hypertension




C. BMI ≥ 30 Kg/m²




D. Metabolic syndrome^a




E. Kidney insufficiency




F. Past/current smokers




G. Former drinkers




H. Non-excessive drinkers




I. Excessive drinkers




J. Poverty




K. Q4 level of lead^b




L. Q4 level of cadmium^b



M. Q4 level of total PCB^c



A. Prevalence



B. Distribution of advanced fibrosis

